180 related articles for article (PubMed ID: 32810737)
1. The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients.
Marcello A; Civra A; Milan Bonotto R; Nascimento Alves L; Rajasekharan S; Giacobone C; Caccia C; Cavalli R; Adami M; Brambilla P; Lembo D; Poli G; Leoni V
Redox Biol; 2020 Sep; 36():101682. PubMed ID: 32810737
[TBL] [Abstract][Full Text] [Related]
2. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
3. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
4. 25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor.
Zu S; Deng YQ; Zhou C; Li J; Li L; Chen Q; Li XF; Zhao H; Gold S; He J; Li X; Zhang C; Yang H; Cheng G; Qin CF
Cell Res; 2020 Nov; 30(11):1043-1045. PubMed ID: 32811977
[No Abstract] [Full Text] [Related]
5. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
[TBL] [Abstract][Full Text] [Related]
6. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
8. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S; Ko M; Lee J; Choi I; Byun SY; Park S; Shum D; Kim S
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366720
[TBL] [Abstract][Full Text] [Related]
9. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
[TBL] [Abstract][Full Text] [Related]
10. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
[TBL] [Abstract][Full Text] [Related]
13. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
14. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
15. Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.
Liu F; Cai ZB; Huang JS; Yu WY; Niu HY; Zhang Y; Sui DM; Wang F; Xue LZ; Xu AF
Pathog Dis; 2020 Jun; 78(4):. PubMed ID: 32592396
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
Magro G
Travel Med Infect Dis; 2020; 37():101685. PubMed ID: 32334088
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2 and the safety margins of cell-based biological medicinal products.
Modrof J; Kerschbaum A; Farcet MR; Niemeyer D; Corman VM; Kreil TR
Biologicals; 2020 Nov; 68():122-124. PubMed ID: 32891497
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
19. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
[TBL] [Abstract][Full Text] [Related]
20. Potent antiviral effect of silver nanoparticles on SARS-CoV-2.
Jeremiah SS; Miyakawa K; Morita T; Yamaoka Y; Ryo A
Biochem Biophys Res Commun; 2020 Nov; 533(1):195-200. PubMed ID: 32958250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]